Apretude
(cabotegravir long-acting for PrEP)
Apretude is an HIV-1 integrase strand transfer inhibitor (INSTI).
Registrational Trials
About the HIV Prevention Trials Network (HPTN)
The HIV Prevention Trials Network (HPTN) is a worldwide, collaborative clinical trials network that brings together investigators, ethicists, community members, and other partners to develop and test the safety and efficacy of interventions designed to prevent the acquisition and transmission of HIV. The National Institutes of Health, the National Institute of Mental Health, and the National Institute on Drug Abuse co-fund the HPTN.3
HPTN 083
A phase 2b/3 double-blind safety and efficacy study of injectable cabotegravir compared to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis in HIV-uninfected cisgender men and transgender women who have sex with men.1
HPTN 084
A phase 3 double-blind safety and efficacy study of long-acting, injectable cabotegravir compared to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis in HIV-uninfected cisgender women.2
References:
- Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021; 385:595-608.
- Delany-Moretlwe S, Hughes J, Bock P, et al. Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: interim results from HPTN 084. J Int AIDS Soc. 2021;24: SUPPL 1 (8).
- HPTN. About the HPTN. Accessed October 25, 2021. https://www.hptn.org/about